Sahota Pharma Limited

Sahota Pharma Limited
Statement of Financial Position
As at 31 August 2025

	Notes	2025 £	2024 £
Current assets
Debtors	3	4,896	0
Cash at bank and in hand		1,048	52,938
		5,944	52,938
Creditors: amount falling due within one year	4	(4,606)	(23,484)
Net current assets		1,338	29,454

Total assets less current liabilities		1,338	29,454
Net assets		1,338	29,454

Capital and reserves
Called up share capital	5	100	100
Profit and loss account		1,238	29,354
Shareholders' funds		1,338	29,454

For the year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The financial statements were approved by the director on 22 May 2026 and were signed by:

-------------------------------
Manpreet SAHOTA
Director

Sahota Pharma Limited
Notes to the Financial Statements
For the year ended 31 August 2025

General Information

Sahota Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 14300332, registration address 16 Bloomfield Drive, Billingham, Durham, TS22 5FA.

The presentation currency is £ sterling.

Accounting policies

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.

The financial statements are prepared in sterling which is the functional currency of the company.

Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

Taxation

Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted

Dividends

Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.

Provisions

Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.

2.	Average number of employees Average number of employees during the year was 0 (2024 : 0).

Debtors: amounts falling due within one year

	2025 £		2024 £
Other Debtors	4,896		0
	4,896		0

Creditors: amount falling due within one year

	2025 £	2024 £
Corporation Tax	4,606	16,917
Accrued Expenses	0	650
Directors' Current Accounts	0	5,917
	4,606	23,484

Share Capital

Allotted, called up and fully paid	2025 £		2024 £
100 Class A shares of £0.01 each	1		1
	1		1

Registered Number: 14300332
England and Wales
SAHOTA PHARMA LIMITED

Unaudited Financial Statements

Period of accounts Start date: 01 September 2024 End date: 31 August 2025